---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-180750"
form_type: "8-K"
ticker: "PHAT"
cik: "0001783183"
company_name: "Phathom Pharmaceuticals, Inc."
filed_at: "2024-07-18T23:59:59+00:00"
generated_at: "2026-05-31T19:46:23.403849+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phathom gets FDA approval for VOQUEZNA to treat heartburn in Non-Erosive GERD

## Summary
- FDA approved VOQUEZNA (vonoprazan) 10 mg tablets for relief of heartburn associated with Non-Erosive GERD in adults.
- This is the third FDA approval for VOQUEZNA; also approved for Erosive GERD and H. pylori eradication.
- Approximately 45 million US adults have Non-Erosive GERD; about 15 million treated with prescription medicine annually.
- Non-Erosive GERD is the largest GERD category, characterized by reflux symptoms without esophageal erosions.

## SEC filing metadata
- accession: 0001193125-24-180750
- form_type: 8-K
- ticker: PHAT
- cik: 0001783183
- company_name: Phathom Pharmaceuticals, Inc.
- filed_at: 2024-07-18T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1783183/000119312524180750/0001193125-24-180750-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1783183/000119312524180750/d812423d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-180750
- JSON: https://secwatch.observer/filing/0001193125-24-180750.json
- Plain text: https://secwatch.observer/filing/0001193125-24-180750.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.